Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Liver Diseases

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 127 articles:
HTML format
Text format



Single Articles


    March 2019

  1. Hepatic Stem Cells.
    Anticancer Res. 2019;39:1631.
    PubMed     Text format    


  2. SCHNAPAUFF D, Tegel BR, Powerski MJ, Colletini F, et al
    Interstitial Brachytherapy in Combination With Previous Transarterial Embolization in Patients With Unresectable Hepatocellular Carcinoma.
    Anticancer Res. 2019;39:1329-1336.
    PubMed     Text format     Abstract available


  3. XU X, Gao D, Yuan X, Liu LI, et al
    beta-Catenin Expression Correlates With Prognosis in Hepatocellular Carcinoma Patients Treated With Transcatheter Arterial Chemoembolization.
    Anticancer Res. 2019;39:1129-1134.
    PubMed     Text format     Abstract available


  4. NISHIE A, Akahori S, Asayama Y, Ishigami K, et al
    Prediction of Liver Fibrosis Using CT Under Respiratory Control: New Attempt Using Deformation Vectors Obtained by Non-rigid Registration Technique.
    Anticancer Res. 2019;39:1417-1424.
    PubMed     Text format     Abstract available


  5. ORTEGA-GRANADOS AL, Artal-Cortes A, Aguiar-Bujanda D, Oramas J, et al
    Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced EGFR Mutation-positive Non-small-cell Lung Cancer.
    Anticancer Res. 2019;39:1317-1328.
    PubMed     Text format     Abstract available


  6. YANO Y, Yoshimatsu K, Yokomizo H, Sagawa M, et al
    Enhancement of the Marginal Area in Colorectal Cancer Liver Metastasis on Computed Tomography Correlates With Microvessel Density and Clinicopathological Factors.
    Anticancer Res. 2019;39:1301-1308.
    PubMed     Text format     Abstract available


  7. KEMPER M, Strohm T, Grupp K, Ghadban T, et al
    Increase of CD45-positive Immune Cells in Liver Parenchyma Indicates a More Favorable Prognosis for Patients With Barrett's Cancer.
    Anticancer Res. 2019;39:1191-1196.
    PubMed     Text format     Abstract available


    February 2019
  8. HARIMOTO N, Hoshino K, Muranushi R, Hagiwara K, et al
    Impact of Metabolic Parameters of (18)F-Fluorodeoxyglucose Positron-emission Tomography After Hepatic Resection in Patients With Intrahepatic Cholangiocarcinoma.
    Anticancer Res. 2019;39:971-977.
    PubMed     Text format     Abstract available


  9. ARIMA K, Nitta H, Beppu T, Nakagawa S, et al
    Impact of Repeated Hepatectomy on Liver Regeneration in Hepatocellular Carcinoma: A Propensity Score-based Analysis.
    Anticancer Res. 2019;39:965-970.
    PubMed     Text format     Abstract available


  10. WATANABE A, Harimoto N, Araki K, Kubo N, et al
    Absolute Neutrophil Count Predicts Postoperative Prognosis in Mass-forming Intrahepatic Cholangiocarcinoma.
    Anticancer Res. 2019;39:941-947.
    PubMed     Text format     Abstract available


  11. YAMAO T, Yamashita YI, Imai K, Umezaki N, et al
    Clinical Significance of Preoperative Hepatocellular Carcinoma With High Lens culinaris Agglutinin-reactive Fraction of Alpha-Fetoprotein, But Low Alpha-Fetoprotein.
    Anticancer Res. 2019;39:883-889.
    PubMed     Text format     Abstract available


  12. CHEN JY, Huang WC, Wei CT, Chien PH, et al
    The C-Terminus of Hepatitis B Virus-encoded X Protein Is Required for Lapatinib Sensitivity in Hepatocellular Carcinoma Cells.
    Anticancer Res. 2019;39:721-726.
    PubMed     Text format     Abstract available


  13. WEI CT, Chen LC, Hsiang YP, Hung YJ, et al
    Chrysin-induced ERK1/2 Phosphorylation Enhances the Sensitivity of Human Hepatocellular Carcinoma Cells to Sorafenib.
    Anticancer Res. 2019;39:695-701.
    PubMed     Text format     Abstract available


    January 2019
  14. SEO S, Yoh T, Morino K, Fuji H, et al
    The Relationship Between (18)F-FDG Uptake on PET/CT and Markers of Systemic Inflammatory Response in Patients Undergoing Surgery for Intrahepatic Cholangiocarcinoma.
    Anticancer Res. 2019;39:341-346.
    PubMed     Text format     Abstract available


    December 2018
  15. MOCHIZUKI K, Kawai M, Odate T, Tahara I, et al
    SMARCB1/INI1 Is Diagnostically Useful in Distinguishing alpha-Fetoprotein-producing Gastric Carcinoma from Hepatocellular Carcinoma.
    Anticancer Res. 2018;38:6865-6868.
    PubMed     Text format     Abstract available


  16. WU CY, Jan YJ, Ko BS, Wu YJ, et al
    Prognostic Significance of 14-3-3epsilon, Aldo-keto Reductase Family 1 B10 and Metallothionein-1 in Hepatocellular Carcinoma.
    Anticancer Res. 2018;38:6855-6863.
    PubMed     Text format     Abstract available


  17. VALAKH V, Gresswell S, Kirichenko A
    Outcomes of Stereotactic Body Radiotherapy for Hepatocellular Carcinoma with Severe Cirrhosis and Ineligibility for Transplant.
    Anticancer Res. 2018;38:6815-6820.
    PubMed     Text format     Abstract available


  18. WAKIYAMA H, Masuda T, Motomura Y, Hu Q, et al
    Cytolytic Activity (CYT) Score Is a Prognostic Biomarker Reflecting Host Immune Status in Hepatocellular Carcinoma (HCC).
    Anticancer Res. 2018;38:6631-6638.
    PubMed     Text format     Abstract available


    November 2018
  19. TOSHIMA T, Yoshizumi T, Ikegami T, Harada N, et al
    Impact of Osteopenia in Liver Cirrhosis: Special Reference to Standard Bone Mineral Density with Age.
    Anticancer Res. 2018;38:6465-6471.
    PubMed     Text format     Abstract available


  20. SO S, Komatsu S, Takebe A, Kido M, et al
    Novel Extracorporeal Hemoperfusion System for Hepatic Arterial Infusion of Cisplatin.
    Anticancer Res. 2018;38:6445-6452.
    PubMed     Text format     Abstract available


  21. XU J, Noda C, Erickson A, Mokkarala M, et al
    Radiofrequency Ablation vs. Cryoablation for Localized Hepatocellular Carcinoma: A Propensity-matched Population Study.
    Anticancer Res. 2018;38:6381-6386.
    PubMed     Text format     Abstract available


  22. MASUDA T, Margonis GA, Andreatos N, Wang J, et al
    Combined Hepatic Resection and Radio-frequency Ablation for Patients with Colorectal Cancer Liver Metastasis: A Viable Option for Patients with a Large Number of Tumors.
    Anticancer Res. 2018;38:6353-6360.
    PubMed     Text format     Abstract available


  23. MASUISHI T, Taniguchi H, Eto T, Komori A, et al
    Morphologic Response and Tumor Shrinkage as Early Predictive Markers in Unresectable Colorectal Liver Metastases.
    Anticancer Res. 2018;38:6501-6506.
    PubMed     Text format     Abstract available


  24. PALKOVICS A, Vereczkei A, Kalmar KN, Fincsur A, et al
    The Issue of Survival After Colorectal Liver Metastasis Surgery: Parenchyma Sparing vs. Radicality.
    Anticancer Res. 2018;38:6431-6438.
    PubMed     Text format     Abstract available


    October 2018
  25. THANGARAJAH F, Vogel C, Pahmeyer C, Eichler C, et al
    Profile and Outcome of Supraclavicular Metastases in Patients with Metastatic Breast Cancer: Discordance of Receptor Status Between Primary and Metastatic Site.
    Anticancer Res. 2018;38:6023-6026.
    PubMed     Text format     Abstract available


  26. COLLOT T, Fumet JD, Klopfenstein Q, Vincent J, et al
    Bevacizumab-based Chemotherapy for Poorly-differentiated Neuroendocrine Tumors.
    Anticancer Res. 2018;38:5963-5968.
    PubMed     Text format     Abstract available


  27. TAKAMORI S, Takada K, Toyokawa G, Azuma K, et al
    PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:5897-5901.
    PubMed     Text format     Abstract available


  28. SUGIYAMA K, Narita Y, Mitani S, Honda K, et al
    Baseline Sarcopenia and Skeletal Muscle Loss During Chemotherapy Affect Survival Outcomes in Metastatic Gastric Cancer.
    Anticancer Res. 2018;38:5859-5866.
    PubMed     Text format     Abstract available


    September 2018
  29. JIANG P, Gu L, Zhou Y, Zhao Y, et al
    Synchronous Laryngeal Squamous Cell Carcinoma and Intrahepatic Cholangiocarcinoma Present in an Obese Male with Poor Prognosis.
    Anticancer Res. 2018;38:5547-5550.
    PubMed     Text format     Abstract available


  30. SANO S, Yamamoto Y, Sugiura T, Okamura Y, et al
    The Radiological Differentiation of Hypervascular Intrahepatic Cholangiocarcinoma from Hepatocellular Carcinoma with a Focus on the CT Value on Multi-phase Enhanced CT.
    Anticancer Res. 2018;38:5505-5512.
    PubMed     Text format     Abstract available


  31. JORDAN F, Grundmann N, Schenkirsch G, Markl B, et al
    Impact of Primary Tumor Localization on the Efficacy of Bevacizumab in Metastatic Colorectal Cancer.
    Anticancer Res. 2018;38:5539-5546.
    PubMed     Text format     Abstract available


  32. TRESKA V, Fichtl J, Ludvik J, Bruha J, et al
    Portal Vein Embolization (PVE) Versus PVE with Haematopoietic Stem Cell Application in Patients with Primarily Non-resectable Colorectal Liver Metastases.
    Anticancer Res. 2018;38:5531-5537.
    PubMed     Text format     Abstract available


  33. HEINZE C, Omari J, Othmer M, Hass P, et al
    Image-guided Interstitial Brachytherapy in the Management of Metastasized Anal Squamous Cell Carcinoma.
    Anticancer Res. 2018;38:5401-5407.
    PubMed     Text format     Abstract available


  34. KAWAHARA H, Yoshida S, Tohyama Y, Yanagisawa S, et al
    Serum Carcinoembryonic Antigen Levels Before the First Curative Hepatectomy for Metastatic Colorectal Cancer Is a Predictor of Recurrence.
    Anticancer Res. 2018;38:5351-5355.
    PubMed     Text format     Abstract available


    August 2018
  35. HARIMOTO N, Hoshino H, Muranushi R, Hagiwara K, et al
    Skeletal Muscle Volume and Intramuscular Adipose Tissue Are Prognostic Predictors of Postoperative Complications After Hepatic Resection.
    Anticancer Res. 2018;38:4933-4939.
    PubMed     Text format     Abstract available


  36. YU JI, Choi GS, Lim DH, Lee E, et al
    Treatment of Naive HCC Combined with Segmental or Subsegmental Portal Vein Tumor Thrombosis: Liver Resection Versus TACE Followed by Radiotherapy.
    Anticancer Res. 2018;38:4919-4925.
    PubMed     Text format     Abstract available


  37. ROSSI L, Biagioni C, McCartney A, Moretti E, et al
    Platinum-based Agent and Fluorouracil in Metastatic Breast Cancer: A Retrospective Monocentric Study with a Review of the Literature.
    Anticancer Res. 2018;38:4839-4845.
    PubMed     Text format     Abstract available


  38. MORIMOTO M, Honjo S, Sakamoto T, Uchinaka EI, et al
    Pilot Study of Probe-based Confocal Laser Endomicroscopy with Fluorescein-dripping Method for Liver Tumors.
    Anticancer Res. 2018;38:4775-4781.
    PubMed     Text format     Abstract available


  39. SHIROYAMA T, Suzuki H, Tamiya M, Tamiya A, et al
    Clinical Characteristics of Liver Metastasis in Nivolumab-treated Patients with Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:4723-4729.
    PubMed     Text format     Abstract available


    July 2018
  40. UCHIYAMA H, Komatsu KI, Nakata A, Sato K, et al
    Global Liver Gene Expression Analysis on a Murine Hepatic Steatosis Model Treated with Mulberry (Morus alba L.) Leaf Powder.
    Anticancer Res. 2018;38:4305-4311.
    PubMed     Text format     Abstract available


  41. NOH CK, Wang HJ, Kim CM, Kim J, et al
    EpCAM as a Predictive Marker of Tumor Recurrence and Survival in Patients Who Underwent Surgical Resection for Hepatocellular Carcinoma.
    Anticancer Res. 2018;38:4101-4109.
    PubMed     Text format     Abstract available


  42. KOGA Y, Beppu T, Miyata T, Kitano Y, et al
    Predicting Poorly Differentiated Hepatocellular Carcinoma that Meets the Milan Criteria.
    Anticancer Res. 2018;38:4093-4099.
    PubMed     Text format     Abstract available


  43. SCHMIDT TM, Liu LI, Abraham IE, Uy AB, et al
    Efficacy and Safety of Sorafenib in a Racially Diverse Patient Population with Advanced Hepatocellular Carcinoma.
    Anticancer Res. 2018;38:4027-4034.
    PubMed     Text format     Abstract available


  44. TSAI TJ, Chao WY, Chen CC, Chen YJ, et al
    Gelsolin-like Actin-capping Protein (CapG) Overexpression in the Cytoplasm of Human Hepatocellular Carcinoma, Associated with Cellular Invasion, Migration and Tumor Prognosis.
    Anticancer Res. 2018;38:3943-3950.
    PubMed     Text format     Abstract available


  45. INAGAWA H, Saika T, Nishiyama N, Nisizawa T, et al
    Dewaxed Brown Rice Feed Improves Fatty Liver in Obese and Diabetic Model Mice.
    Anticancer Res. 2018;38:4339-4345.
    PubMed     Text format     Abstract available


  46. JELSKI W, Wolszczak-Biedrzycka B, Zasimowicz-Majewska E, Orywal K, et al
    Alcohol Dehydrogenase Isoenzymes and Aldehyde Dehydrogenase Activity in the Serum of Patients with Non-alcoholic Fatty Liver Disease.
    Anticancer Res. 2018;38:4005-4009.
    PubMed     Text format     Abstract available


  47. MIRKA H, Duras P, Baxa J, Korcakova E, et al
    Contribution of Computed Tomographic Angiography to Pretreatment Planning of Radio-embolization of Liver Tumors.
    Anticancer Res. 2018;38:3825-3829.
    PubMed     Text format     Abstract available


    June 2018
  48. SHIBA S, Shibuya K, Katoh H, Koyama Y, et al
    No Deterioration in Clinical Outcomes of Carbon Ion Radiotherapy for Sarcopenia Patients with Hepatocellular Carcinoma.
    Anticancer Res. 2018;38:3579-3586.
    PubMed     Text format     Abstract available


  49. ANDO K, Sakoda M, Ueno S, Hiwatashi K, et al
    Clinical Implication of the Relationship Between High Mobility Group Box-1 and Tumor Differentiation in Hepatocellular Carcinoma.
    Anticancer Res. 2018;38:3411-3418.
    PubMed     Text format     Abstract available


  50. SAWAZAKI S, Numata M, Morita J, Maezawa Y, et al
    Safety of Laparoscopic Surgery for Colorectal Cancer in Patients with Severe Comorbidities.
    Anticancer Res. 2018;38:3767-3772.
    PubMed     Text format     Abstract available


  51. TRESKA V, Topolcan O, Zoubkova V, Treskova I, et al
    Perioperative Tumour Marker Levels as Prognostic Factors for Surgical Treatment of Breast Cancer Liver Metastases.
    Anticancer Res. 2018;38:3647-3652.
    PubMed     Text format     Abstract available


    May 2018
  52. MACHAIRAS N, Papaconstantinou D, Stamopoulos P, Prodromidou A, et al
    The Emerging Role of Laparoscopic Liver Resection in the Treatment of Recurrent Hepatocellular Carcinoma: A Systematic Review.
    Anticancer Res. 2018;38:3181-3186.
    PubMed     Text format     Abstract available


  53. YOSHIDA M, Beppu T, Shiraishi S, Tsuda N, et al
    Liver Function in Areas of Hepatic Venous Congestion After Hepatectomy for Liver Cancer: (99m)Tc-GSA SPECT/CT Fused Imaging Study.
    Anticancer Res. 2018;38:3089-3095.
    PubMed     Text format     Abstract available


  54. IWABU J, Namikawa T, Tsuda S, Kitagawa H, et al
    Successful Distal Gastrectomy for Gastric Cancer with Child-Pugh Class B Alcoholic Liver Cirrhosis.
    Anticancer Res. 2018;38:3085-3087.
    PubMed     Text format     Abstract available


  55. LAI JZ, Zhou Y, Cao D
    Synchronous Pancreatic Ductal Adenocarcinoma and Hepatocellular Carcinoma: Report of a Case and Review of the Literature.
    Anticancer Res. 2018;38:3009-3012.
    PubMed     Text format     Abstract available


  56. SHIH YL, Huang YH, Lin KH, Chu YD, et al
    Identification of Functional Thyroid Stimulating Hormone Receptor and TSHR Gene Mutations in Hepatocellular Carcinoma.
    Anticancer Res. 2018;38:2793-2802.
    PubMed     Text format     Abstract available


  57. HABERL EM, Pohl R, Rein-Fischboeck L, Feder S, et al
    Chemerin in a Mouse Model of Non-alcoholic Steatohepatitis and Hepatocarcinogenesis.
    Anticancer Res. 2018;38:2649-2657.
    PubMed     Text format     Abstract available


  58. ALFONSO PG, Podesta MC, Martin AM, Codeisido MB, et al
    Chemotherapy Plus Bevacizumab as Neoadjuvant or Conversion Treatment in Patients with Colorectal Liver Metastases.
    Anticancer Res. 2018;38:3069-3077.
    PubMed     Text format     Abstract available


  59. CHANG J, Charalel R, Noda C, Ramaswamy R, et al
    Liver-dominant Breast Cancer Metastasis: A Comparative Outcomes Study of Chemoembolization Versus Radioembolization.
    Anticancer Res. 2018;38:3063-3068.
    PubMed     Text format     Abstract available


  60. DESHWAR A, Margonis GA, Andreatos N, Barbon C, et al
    Double KRAS and BRAF Mutations in Surgically Treated Colorectal Cancer Liver Metastases: An International, Multi-institutional Case Series.
    Anticancer Res. 2018;38:2891-2895.
    PubMed     Text format     Abstract available


  61. NASSEREDDINE S, Alsubait S, Tabbara I
    Sinusoidal Obstruction Syndrome (Veno-occlusive Disease) Following Hematopoietic Stem Cell Transplant: Insights and Therapeutic Advances.
    Anticancer Res. 2018;38:2597-2605.
    PubMed     Text format     Abstract available


    April 2018
  62. KANG WH, Tak E, Hwang S, Song GW, et al
    Metformin-associated Chemopreventive Effects on Recurrence After Hepatic Resection of Hepatocellular Carcinoma: From In Vitro to a Clinical Study.
    Anticancer Res. 2018;38:2399-2407.
    PubMed     Text format     Abstract available


  63. TSAI JJ, Hsu FT, Pan PJ, Chen CW, et al
    Amentoflavone Enhances the Therapeutic Efficacy of Sorafenib by Inhibiting Anti-apoptotic Potential and Potentiating Apoptosis in Hepatocellular Carcinoma In Vivo.
    Anticancer Res. 2018;38:2119-2125.
    PubMed     Text format     Abstract available


  64. SATAKE T, Suetsugu A, Nakamura M, Hasegawa K, et al
    Differential Organ-targeting and Cellular Characteristics of Metastatic Human Pancreatic Cancer Cell Lines in Mouse Models.
    Anticancer Res. 2018;38:1927-1935.
    PubMed     Text format     Abstract available


    March 2018
  65. TOYA R, Saito T, Shiraishi S, Kai Y, et al
    Dose-function Histogram Evaluation Using (99m)Tc-GSA SPECT/CT Images for Stereotactic Body Radiation Therapy Planning for Hepatocellular Carcinoma Patients: A Dosimetric Parameter Comparison.
    Anticancer Res. 2018;38:1511-1516.
    PubMed     Text format     Abstract available


  66. OKANO N, Kasuga A, Kawai K, Yamauchi Y, et al
    The Modified Glasgow Prognostic Score in Patients with Gemcitabine-refractory Biliary Tract Cancer.
    Anticancer Res. 2018;38:1755-1761.
    PubMed     Text format     Abstract available


  67. FILIPESCU A, Balescu I, Bacalbasa N
    Upper Abdominal Resection for Isolated Metastatic Lesions in Recurrent Cervical Cancer.
    Anticancer Res. 2018;38:1659-1663.
    PubMed     Text format     Abstract available


  68. KINOSHITA K, Beppu T, Miyata T, Kuramoto K, et al
    A Case of 15-Year Recurrence-free Survival After Microwave Coagulation Therapy for Liver Metastasis from Gastric Cancer.
    Anticancer Res. 2018;38:1595-1598.
    PubMed     Text format     Abstract available


  69. MORIS D, Ntanasis-Stathopoulos I, Tsilimigras DI, Vagios S, et al
    Update on Surgical Management of Small Bowel Neuroendocrine Tumors.
    Anticancer Res. 2018;38:1267-1278.
    PubMed     Text format     Abstract available


    February 2018
  70. IMAI K, Yamashita YI, Yusa T, Nakao Y, et al
    Microvascular Invasion in Small-sized Hepatocellular Carcinoma: Significance for Outcomes Following Hepatectomy and Radiofrequency Ablation.
    Anticancer Res. 2018;38:1053-1060.
    PubMed     Text format     Abstract available


  71. TSUKAMOTO M, Yamashita YI, Imai K, Umezaki N, et al
    Long-term Favorable Outcomes of Radiofrequency Ablation for Hepatocellular Carcinoma as an Initial Treatment: A Single-center Experience Over a 10-Year Period.
    Anticancer Res. 2018;38:1047-1052.
    PubMed     Text format     Abstract available


  72. SATTLER T, Bredt C, Surwald S, Rust C, et al
    Efficacy and Safety of Drug Eluting Bead TACE with Microspheres <150 mum for the Treatment of Hepatocellular Carcinoma.
    Anticancer Res. 2018;38:1025-1032.
    PubMed     Text format     Abstract available


  73. UEMOTO K, Doi H, Shiomi H, Yamada K, et al
    Clinical Assessment of Micro-residual Tumors during Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma.
    Anticancer Res. 2018;38:945-954.
    PubMed     Text format     Abstract available


  74. HORTON CE, Kamal M, Leslie M, Zhang R, et al
    Circulating Tumor Cells Accurately Predicting Progressive Disease After Treatment in a Patient with Non-small Cell Lung Cancer Showing Response on Scans.
    Anticancer Res. 2018;38:1073-1076.
    PubMed     Text format     Abstract available


  75. OSADA S, Gotoh A, Yokoi R, Tsuchiya H, et al
    Effective Timing of Surgical Resection of Colorectal Cancer Liver Metastases During Chemotherapy.
    Anticancer Res. 2018;38:737-743.
    PubMed     Text format     Abstract available


  76. DOI H, Beppu N, Kitajima K, Kuribayashi K, et al
    Stereotactic Body Radiation Therapy for Liver Tumors: Current Status and Perspectives.
    Anticancer Res. 2018;38:591-599.
    PubMed     Text format     Abstract available


  77. CEAUSU AR, Ciolofan A, Cimpean AM, Magheti A, et al
    The Mesenchymal-Epithelial and Epithelial-Mesenchymal Cellular Plasticity of Liver Metastases with Digestive Origin.
    Anticancer Res. 2018;38:811-816.
    PubMed     Text format     Abstract available


    January 2018
  78. KURAMOTO K, Beppu T, Nitta H, Imai K, et al
    Hepatic Resection Followed by Hepatic Arterial Infusion Chemotherapy for Hepatocellular Carcinoma with Intrahepatic Dissemination.
    Anticancer Res. 2018;38:525-531.
    PubMed     Text format     Abstract available


  79. YOSHIMOTO T, Imura S, Morine Y, Ikemoto T, et al
    The Outcome of Sorafenib Therapy on Unresectable Hepatocellular Carcinoma: Experience of Conversion and Salvage Hepatectomy.
    Anticancer Res. 2018;38:501-507.
    PubMed     Text format     Abstract available


  80. SPELT L, Sasor A, Ansari D, Hilmersson KS, et al
    The Prognostic Role of Cancer Stem Cell Markers for Long-term Outcome After Resection of Colonic Liver Metastases.
    Anticancer Res. 2018;38:313-320.
    PubMed     Text format     Abstract available


  81. VIRGILIO E, Cavallini M
    Managing Focal Nodular Hyperplasia of the Liver: Surgery or Minimally-invasive Approaches? A Review of the Preferable Treatment Options.
    Anticancer Res. 2018;38:33-36.
    PubMed     Text format     Abstract available


    December 2017
  82. TSUKAMOTO M, Yamashita YI, Imai K, Umezaki N, et al
    Predictors of Cure of Intrahepatic Cholangiocarcinoma After Hepatic Resection.
    Anticancer Res. 2017;37:6971-6975.
    PubMed     Text format     Abstract available


  83. LIANG YH, Shao YY, Chen HM, Cheng AL, et al
    Irinotecan and Oxaliplatin Might Provide Equal Benefit as Adjuvant Chemotherapy for Patients with Resectable Synchronous Colon Cancer and Liver-confined Metastases: A Nationwide Database Study.
    Anticancer Res. 2017;37:7095-7104.
    PubMed     Text format     Abstract available


  84. MIYATA T, Beppu T, Higashi T, Nakagawa S, et al
    A Glissonean Approach with Individual Isolation During Right Hemi-Hepatectomy After Portal Vein Embolization.
    Anticancer Res. 2017;37:7069-7071.
    PubMed     Text format     Abstract available


  85. SHIBATA H, Ohike N, Norose T, Isobe T, et al
    Mucinous Cystic Neoplasms Lined by Abundant Mucinous Epithelium Frequently Involve KRAS Mutations and Malignant Progression.
    Anticancer Res. 2017;37:7063-7068.
    PubMed     Text format     Abstract available


  86. CAIVANO D, Valeriani M, Russo I, Bonome P, et al
    Stereotactic Body Radiation Therapy in Primary and Metastatic Liver Disease.
    Anticancer Res. 2017;37:7005-7010.
    PubMed     Text format     Abstract available


    November 2017
  87. BAI YC, Hsia YC, Lin YT, Chen KH, et al
    Effect of Tumor Microenvironment on Selective Uptake of Boric Acid in HepG2 Human Hepatoma Cells.
    Anticancer Res. 2017;37:6347-6353.
    PubMed     Text format     Abstract available


  88. CIRIMBEI C, Rotaru V, Chitoran E, Pavaleanu O, et al
    Immediate and Long-term Results of Radiofrequency Ablation for Colorectal Liver Metastases.
    Anticancer Res. 2017;37:6489-6494.
    PubMed     Text format     Abstract available


  89. SATONAKA H, Ishida K, Takai M, Koide R, et al
    (-)-Epigallocatechin-3-gallate Down-regulates Doxorubicin-induced Overexpression of P-glycoprotein Through the Coordinate Inhibition of PI3K/Akt and MEK/ERK Signaling Pathways.
    Anticancer Res. 2017;37:6071-6077.
    PubMed     Text format     Abstract available


    October 2017
  90. IMURA S, Yamada S, Saito YU, Iwahashi S, et al
    miR-223 and Stathmin-1 Expression in Non-tumor Liver Tissue of Patients with Hepatocellular Carcinoma.
    Anticancer Res. 2017;37:5877-5883.
    PubMed     Text format     Abstract available


  91. MORINE Y, Imura S, Ikemoto T, Iwahashi S, et al
    CD44 Expression Is a Prognostic Factor in Patients with Intrahepatic Cholangiocarcinoma After Surgical Resection.
    Anticancer Res. 2017;37:5701-5705.
    PubMed     Text format     Abstract available


  92. RATHMANN N, Kara K, Budjan J, Henzler T, et al
    Parenchymal Liver Blood Volume and Dynamic Volume Perfusion CT Measurements of Hepatocellular Carcinoma in Patients Undergoing Transarterial Chemoembolization.
    Anticancer Res. 2017;37:5681-5685.
    PubMed     Text format     Abstract available


  93. IKEMOTO T, Shimada M, Ishikawa D, Kawashita Y, et al
    Peripheral Tr1 and Foxp3+ Treg as Markers of Recurrent Malignancies in Patients with Hepato-Biliary Pancreatic Cancers.
    Anticancer Res. 2017;37:5541-5552.
    PubMed     Text format     Abstract available


  94. KISHIMOTO S, Yasuda M, Fukushima S
    Changes in the Expression of Various Transporters as Influencing Factors of Resistance to Cisplatin.
    Anticancer Res. 2017;37:5477-5484.
    PubMed     Text format     Abstract available


    September 2017
  95. SAKABE T, Azumi J, Umekita Y, Toriguchi K, et al
    Expression of Cancer Stem Cell-associated DKK1 mRNA Serves as Prognostic Marker for Hepatocellular Carcinoma.
    Anticancer Res. 2017;37:4881-4888.
    PubMed     Text format     Abstract available


  96. BI YE, Zhou Y, Wang M, Li L, et al
    Targeted Delivery of Cordycepin to Liver Cancer Cells Using Transferrin-conjugated Liposomes.
    Anticancer Res. 2017;37:5207-5214.
    PubMed     Text format     Abstract available


  97. CICERO G, Lo Re G, DE Luca R, Vernuccio F, et al
    Role of Densitometric Criteria in Evaluation of Effectiveness of Antiangiogenic Therapies in Metastatic Colorectal Cancer: An Italian Clinical Experience.
    Anticancer Res. 2017;37:5187-5192.
    PubMed     Text format     Abstract available


  98. DIVELLA R, Daniele A, DE Luca R, Simone M, et al
    Circulating Levels of VEGF and CXCL1 Are Predictive of Metastatic Organotropismin in Patients with Colorectal Cancer.
    Anticancer Res. 2017;37:4867-4871.
    PubMed     Text format     Abstract available


    August 2017
  99. WANG L, Liu M, Liu L, Zheng Y, et al
    MR-guided Percutaneous Biopsy of Focal Hepatic Dome Lesions with Free-hand Combined with MR Fluoroscopy Using 1.0-T Open High-field Scanner.
    Anticancer Res. 2017;37:4635-4641.
    PubMed     Text format     Abstract available


  100. GONG Z, Chi C, Huang X, Chu H, et al
    Cyclophilin A Is Overexpressed in Hepatocellular Carcinoma and Is Associated with the Cell Cycle.
    Anticancer Res. 2017;37:4443-4447.
    PubMed     Text format     Abstract available


  101. ZHANG WG, Yin XC, Liu XF, Meng KW, et al
    Puerarin Induces Hepatocellular Carcinoma Cell Apoptosis Modulated by MAPK Signaling Pathways in a Dose-dependent Manner.
    Anticancer Res. 2017;37:4425-4431.
    PubMed     Text format     Abstract available


    July 2017
  102. HARADA N, Yoshizumi T, Yamashita YI, Soejima Y, et al
    Impact and Prediction of Lymph Node Involvement in Patients with Intrahepatic Cholangiocarcinoma After Curative Resection.
    Anticancer Res. 2017;37:3763-3769.
    PubMed     Text format     Abstract available


  103. KRAUTBAUER S, Weiss TS, Wiest R, Schacherer D, et al
    Diagnostic Value of Systemic Cholesteryl Ester/Free Cholesterol Ratio in Hepatocellular Carcinoma.
    Anticancer Res. 2017;37:3527-3535.
    PubMed     Text format     Abstract available


  104. HAYASHI T, Yamashita T, Okada H, Oishi N, et al
    A Novel mTOR Inhibitor; Anthracimycin for the Treatment of Human Hepatocellular Carcinoma.
    Anticancer Res. 2017;37:3397-3403.
    PubMed     Text format     Abstract available


  105. ISHII F, Yoshida Y, Yamauchi Y, Aisu N, et al
    Hepatectomy for Liver Metastases of Colorectal Cancer After Adoptive Chemoimmunotherapy Using Activated alphabeta T-cells.
    Anticancer Res. 2017;37:3933-3939.
    PubMed     Text format     Abstract available


  106. SHIBA I, Kouzaki R, Yamada H, Endo Y, et al
    Design and Synthesis of Novel Anti-metastatic Hypoxic Cytotoxin TX-2137 Targeting AKT Kinase.
    Anticancer Res. 2017;37:3877-3883.
    PubMed     Text format     Abstract available


  107. SETO K, Sakabe T, Itaba N, Azumi J, et al
    A Novel Small-molecule WNT Inhibitor, IC-2, Has the Potential to Suppress Liver Cancer Stem Cells.
    Anticancer Res. 2017;37:3569-3579.
    PubMed     Text format     Abstract available


  108. NAKAMURA M, Suetsugu A, Hasegawa K, Matsumoto T, et al
    Choline-Deficient-Diet-Induced Fatty Liver Is a Metastasis-Resistant Microenvironment.
    Anticancer Res. 2017;37:3429-3434.
    PubMed     Text format     Abstract available


    June 2017
  109. WAKIYAMA S, Matsumoto M, Haruki K, Gocho T, et al
    Clinical Features and Outcome of Surgical Patients with Non-B Non-C Hepatocellular Carcinoma.
    Anticancer Res. 2017;37:3207-3213.
    PubMed     Text format     Abstract available


  110. MATSUMOTO T, Ichikawa H, Imai J, Hayashi T, et al
    Feasibility and Safety of Repeated Transarterial Chemoembolization Using Miriplatin-Lipiodol Suspension for Hepatocellular Carcinoma.
    Anticancer Res. 2017;37:3183-3187.
    PubMed     Text format     Abstract available


  111. LIN CL, Chien RN, Liang KH, Ke PY, et al
    Intrahepatic HCV RNA Level and Genotype 1 Independently Associate with Hepatic Reticulon 3 Expression.
    Anticancer Res. 2017;37:2885-2891.
    PubMed     Text format     Abstract available


    May 2017
  112. MIYATA T, Yamashita YI, Yamao T, Umezaki N, et al
    Clinical Benefits of Lymph Node Dissection in Intrahepatic Cholangiocarcinoma: A Retrospective Single-institution Study.
    Anticancer Res. 2017;37:2673-2677.
    PubMed     Text format     Abstract available


  113. HASHIMOTO M, Kobayashi T, Ishiyama K, Ide K, et al
    Predictive Independent Factors for Extrahepatic Metastasis of Hepatocellular Carcinoma Following Curative Hepatectomy.
    Anticancer Res. 2017;37:2625-2631.
    PubMed     Text format     Abstract available


  114. LU LC, Chen PJ, Yeh YC, Hsu CH, et al
    Prescription Patterns of Sorafenib and Outcomes of Patients with Advanced Hepatocellular Carcinoma: A National Population Study.
    Anticancer Res. 2017;37:2593-2599.
    PubMed     Text format     Abstract available


  115. KANAJI N, Kita N, Kadowaki N, Bandoh S, et al
    Fibronectin and Hepatocyte Growth Factor Produced by Lung Fibroblasts Augment Migration and Invasion of Malignant Pleural Mesothelioma Cells.
    Anticancer Res. 2017;37:2393-2400.
    PubMed     Text format     Abstract available


  116. BARABINO M, Gatti A, Santambrogio R, Polizzi M, et al
    Intraoperative Local Ablative Therapies Combined with Surgery for the Treatment of Bilobar Colorectal Liver Metastases.
    Anticancer Res. 2017;37:2743-2750.
    PubMed     Text format     Abstract available


    April 2017
  117. MALKI A, El-Sharkawy A, El Syaed M, Bergmeier S, et al
    Antitumor Activities of the Novel Isosteviol Derivative 10C Against Liver Cancer.
    Anticancer Res. 2017;37:1591-1601.
    PubMed     Text format     Abstract available


  118. TAHARA T, Tahara S, Horiguchi N, Kawamura T, et al
    Telomere Length in Leukocyte DNA in Gastric Cancer Patients and its Association with Clinicopathological Features and Prognosis.
    Anticancer Res. 2017;37:1997-2001.
    PubMed     Text format     Abstract available


  119. OTTAIANO A, Capozzi M, DE Divitiis C, VON Arx C, et al
    Nab-Paclitaxel and Gemcitabine in Advanced Pancreatic Cancer: The One-year Experience of the National Cancer Institute of Naples.
    Anticancer Res. 2017;37:1975-1978.
    PubMed     Text format     Abstract available


  120. HARADA N, Yoshizumi T, Maeda T, Kayashima H, et al
    Preoperative Pancreatic Stiffness by Real-time Tissue Elastography to Predict Pancreatic Fistula After Pancreaticoduodenectomy.
    Anticancer Res. 2017;37:1909-1915.
    PubMed     Text format     Abstract available


    March 2017
  121. DE PASQUALE MD, de Ville de Goyet J, Monti L, Grimaldi C, et al
    Bevacizumab Combined with Chemotherapy in Children Affected by Hepatocellular Carcinoma: a Single-center Experience.
    Anticancer Res. 2017;37:1489-1493.
    PubMed     Text format     Abstract available


  122. ITOH S, Uchiyama H, Ikeda Y, Morita K, et al
    Post-hepatectomy Refractory Ascites in Cirrhotic Patients with Hepatocellular Carcinoma: Risk Factor Analysis to Overcome this Problematic Complication.
    Anticancer Res. 2017;37:1381-1385.
    PubMed     Text format     Abstract available


  123. MARQUES LA, Semprebon SC, Sartori D, DE Fatima A, et al
    Comparison of the Effects of Monastrol and Oxomonastrol on Human Hepatoma Cell Line HepG2/C3A.
    Anticancer Res. 2017;37:1197-1204.
    PubMed     Text format     Abstract available


  124. YOSHIKAWA M, Morine Y, Ikemoto T, Imura S, et al
    Elevated Preoperative Serum CEA Level Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma Through the Epithelial-Mesenchymal Transition.
    Anticancer Res. 2017;37:1169-1175.
    PubMed     Text format     Abstract available


  125. KOMATSU H, Masuda T, Iguchi T, Nambara S, et al
    Clinical Significance of FANCD2 Gene Expression and its Association with Tumor Progression in Hepatocellular Carcinoma.
    Anticancer Res. 2017;37:1083-1090.
    PubMed     Text format     Abstract available


  126. TRESKA V, Fichtl J, Bruha J, Liska V, et al
    Liver Resections for Colorectal Metastases in Patients Aged Over 75 Years.
    Anticancer Res. 2017;37:1529-1533.
    PubMed     Text format     Abstract available


  127. D'ONOFRIO M, Cingarlini S, Ortolani S, Crosara S, et al
    Perfusion CT Changes in Liver Metastases from Pancreatic Neuroendocrine Tumors During Everolimus Treatment.
    Anticancer Res. 2017;37:1305-1311.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: